Treatment of hypertension associated with obstructive sleep apnea syndrome: rihnenidine vs bisoprolol
https://doi.org/10.18705/1607-419X-2007-13-4-280-285
Abstract
The aim of the present study was to compare efficacy of bisoprolol and rilmenidine in patients with 1-2 stage hypertension and obstructive sleep apnea syndrome (OSA). In an open-label controlled randomized study 60 patients received rilmenidine 1-2 mg per day or bisoprolol 5-10 mg per day for 12 weeks. Ambulatory blood pressure monitoring (ABPM) and polysomnography was performed twice initially and at the end of the study. "Office" blood pressure (BP) and 24-hour BP decreased significantly in both groups. However, in rilmenidine group the normalization of diurnal BP index was more frequently observed as well as decrease of apnea index. The results obtained indicate that rilmenidine is equally effective with bisoprolol as antihypertensive medication, but additionally decrease nighttime BP possibly due to decrease of sympathetic overactivity. Revealed effect on parameters of OSA opens a new spheаre of rilmenidine administration in hypertension.
About the Authors
Yu. V. Sviryaev
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
K. T. Kitalaeva
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
Lu. S. Korostovtceva
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
N. E. Zvartau
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
O. P. Rotar
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
A. O. Konradi
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
A. L. Kalinkin
Almazov Federal Heart, Blood and Endocrinology Center, St.Petersburg
Russian Federation
Russian Federation
References
1. Frei M., Kuster L., Gardosch von Krosigk P-P. et al. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect// J. Cardiovasc. Pharmacol. - 1994; 24:S25-S28.
2.
3. Fiorentini C., Guillet C., Guazzi M. Multicenter, double-blind study comparing rilmenidine 1 mg and hydrochlorothiazide 25 mg in 244 patients// Arch Mal Coeur Vaiss. 1989 Dec;82 Spec No 5:39-46;
4.
5. Lotti G., Gianrossi R. Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance// Fortscher Med. 1993; 111:429-432;
6.
7. Scemama M., Fevrier B., Beucler I., Dairou F. Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril// J. Cardiovasc Pharmacol. 1995; 26 (Suppl. 2): S34-S39;
8.
9. Fillastre JP <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fillastre%20JP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
10.
11. Letac B <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Letac%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
12.
13. Galinier F <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Galinier%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
14.
15. Le Bihan G <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Le%20Bihan%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
16.
17. Schwartz J <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Schwartz%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>.
18.
19. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients// Am J Cardiol. <javascript:AL_get(this,%20'jour',%20'Am%20J%20Cardiol.');> 1988 Feb 24;61(7):81D-85D;
20.
21. Kuppers H.E., Jager B., Heghes P.R. et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension// J. Hypertension 1997; 15: 93-97;
22.
23. Panfilov V, Morris AD, Donnelly R, Scemama M, Reid JL. <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=8703663&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum> The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension// Br J Clin Pharmacol. 1995 Dec;40(6):563-9;
24.
25. Dallocchio M., Gosse P., Fillastre J.P. et al. Rilmenidine, a new antihypertensive agent in the first line treatment of essential arterial hypertension. Multicenter double-blind study versus atenolol// Presse Med. 1991 Aug 31-Sep 7;20(27):1265-71. French;
26.
27. Mall G <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mall%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
28.
29. Greber D <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Greber%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
30.
31. Gharenhbaghi H <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gharenhbaghi%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
32.
33. Wiest G <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wiest%20G%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
34.
35. Amann K <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Amann%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
36.
37. Mattfeldt T <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mattfeldt%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>.
38.
39. Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR)--stereological studies on myocytes, capillaries, arteries, and cardiac interstitium// Basic Res Cardiol. <javascript:AL_get(this,%20'jour',%20'Basic%20Res%20Cardiol.');> 1991;86 Suppl 3:33-44
40.
41. Sadowski Z., Szwed H., Kuch-Wocial A. et al. Regression of left ventricular hypertrophy in hypertensive patients after one year treatment with rilmenidine: double-blind, randomised, controlled study versus nifedipine. Lnt Symp 69th Annual Scientific Session of the AHA New Orleans; 1996. Abstract;
42.
43. Van den Buuse M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Van%20den%20Buuse%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>. Pretreatment with quinpirole inhibits the central antihypertensive effects of rilmenidine and alpha-methyldopa in conscious rats// Eur J Pharmacol. <javascript:AL_get(this,%20'jour',%20'Eur%20J%20Pharmacol.');> 1997 Mar 19;322(2-3):191-9;
44.
45. Шляхто Е.В., Конради А.О., Свиряев Ю.В. Основные результаты исследования АЛЬТАИР// Кардиоваскулярная терапия и профилактика. - 2006, №1. - С. 21-30. Шляхто Е.В., Конради А.О. Переносимость терапии рилменидином и его сочетания с амлодипином у больных гипертонической болезнью. (По данным исследования АЛЬТАИР)// Артериальная гипертензия. - 2006, Т.12;
46.
47. Конради А.О., Свиряев Ю.В. Динамика массы тела, уровней глюкозы и липидов плазмы на фоне приема рилменидина в монотерапии и в комбинации с амлодипином (по результатам исследования АЛЬТАИР)// Артериальная гипертензия. - 2006. - Т. 12, №2. - С. 141-144;
48.
49. Kamisaki Y., Ishikawa T., TakaoY. et al. Binding of [3H]p-aminoclonidine to two sites, alpha 2-adrenoceptors and imidazoline binding sites: distribution of imidazoline binding sites in rat brain// Brain Res. 1990; 514 (1):15-21;
50.
51. Stroes JW, Putters J, van Rijn HJ. An improved spectrophotometric procedure for the determination of urinary metanephrines// J Clin Chem Clin Biochem. 1987 Aug;25(8):483-6;
52.
53. Kaan E.C., Bricker R., Frohly P. et al. Effects of agmatine and moxonidine on glucose metabolism: and integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders// J. Cardiac. Risk Factors. - 1995, Vol.5. - P. 10-27;
54.
55. Rosen P., Ohly P., Gleichmann H. Experimental benefit of moxonidine on glucose metabolism// J. Hypertens. - 1997, Vol. 15. - S31-38;
56.
57. Head G.A., Burke S.L. Comparison of renal sympathetic baroreflex effects of rilmenedine and alfa-methylnoradrenaline ventrolateral medulla of the rabbit// J. Hypertens. - 2000, Vol.18. - P.1263-76;
58.
59. Многотомное руководство по неврологии, под ред. Н. И. Гращенкова, т. 1, кн. 1, М., 1959; Clara М., Das Nervensystem des Menschen, 2 Aufl., Lpz., 1953;
60.
61. Eisenhofer G, Friberg P, Pacak K, Goldstein DS, Murphy DL, Tsigos C, Quyyumi AA, Brunner HG, Lenders JW. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism?// Clin Sci (Lond). <javascript:AL_get(this,%20'jour',%20'Clin%20Sci%20(Lond).');> 1995 May;88(5):533-42;
62.
63. Ratge D <http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=%22Ratge%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
64.
65. Gehrke A <http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=%22Gehrke%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
66.
67. Melzner I <http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=%22Melzner%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>
68.
69. Wisser H <http://www.ncbi.nlm.nih.gov/sites/?Db=pubmed&Cmd=Search&Term=%22Wisser%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus>.
70.
71. Free and conjugated catecholamines in human plasma during physical exercise// Clin Exp Pharmacol Physiol. <javascript:AL_get(this,%20'jour',%20'Clin%20Exp%20Pharmacol%20Physiol.');> 1986 Jul;13(7):543-53.
72.
Review
For citations:
Sviryaev Yu.V., Kitalaeva K.T., Korostovtceva L.S., Zvartau N.E., Rotar O.P., Konradi A.O., Kalinkin A.L. Treatment of hypertension associated with obstructive sleep apnea syndrome: rihnenidine vs bisoprolol. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(4):280-285. (In Russ.) https://doi.org/10.18705/1607-419X-2007-13-4-280-285
Views:
1112
Email this article 